All In Biotech

Drug Trial Radar · NCT05718258

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

A Phase 1, Multi-center, Parallel, Open-label, Pharmacokinetic, Safety, and Tolerability Study of Venglustat Given as a Single Dose in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment and in Matched Participants With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jan 18, 2023

Primary completion

Jan 29, 2024

Study completion Jan 29, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 1, four arm, open-label, single dose, multicenter study to evaluate the impact of hepatic impairment on venglustat exposure following treatment with venglustat. The purpose of this study is to assess the effect of mild, moderate, and severe hepatic impairment on PK, safety, and tolerability of venglustat compared with normal hepatic function in male and female participants aged 18 to 79 years. Study details include: * The total study duration per participant will be up to 42 days, including up to 21 days for screening and approximately 21 days from institutionalization to the end of study (EOS). * Institutionalization is mandatory until the activities on D5 have been completed. * Each participant will receive a single dose of venglustat. * For hepatically impaired participants there will be a screening visit, a multi-day institutionalization visit, and 7 site visits after D5 discharge, including the end of study (EOS) visit. * For healthy volunteers there will be a screening visit, a multi-day institutionalization visit and 3 site visits after D5 discharge, including the end of study (EOS) visit.

Conditions

  • Hepatic Function Abnormal

Interventions

  • Venglustat (GZ402671)Drug

    Pharmaceutical form: tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum venglustat plasma concentration observed (Cmax)Time frame: Baseline to Day 20
  2. Area under the plasma concentration versus time curve extrapolated to infinity (AUC)Time frame: Baseline to Day 20

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Inland Empire Liver Foundation Site Number : 8400004

    Rialto, California

  • Clinical Pharmacology of Miami Site Number : 8400002

    Miami, Florida

  • Nucleus Network Site Number : 8400001

    Saint Paul, Minnesota

  • Volunteer Research Group-NOCCR Site Number : 8400003

    Knoxville, Tennessee

  • American Research Corporation Site Number : 8400005

    San Antonio, Texas

  • Investigational Site Number : 2760001

    Kiel, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.